What are your top takeaways in GU Cancers from ASCO 2024?

In terms of practice-changing/informing datasets newly presented at ASCO 2024, here are my top 5:

1. Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy. LBA12004, St...

1. @Dr. First Last: EV-302 PRO/QoL data
2. @Dr. First Last: Dose exposure and association with ORR with EV monotherapy
3. @Dr. First Last: CheckMate 901 - characterization of patients with complete response
4. Antonio Cigliola: SURE-01 neoadjuvant...

My top 3 for prostate cancer were:

1. Abstract 5010: JNJ-69086420 for mCRPC
2. Abstract 5011: ARV-766 for mCRPC
3. Abstract 5012: Tarlatamab for Neuroendocrine Prostate Cancer

1. Abstract 4503, Dr. @Dr. First Last's review of dose received and duration of therapy for EV/pembro in metastatic urothelial ca reassured me that patients do well even with reduced dosing of EV.
   
   
2. Dr. @Dr. First Last's discussion of KIM-1 in response to Dr. Albiges' post hoc analysis of KIM-1 in IMmot...

PSMAfore presented previously showed (177Lu-PSMA-617) prolonged radiographic progression-free survival vs change of androgen receptor pathway inhibitor (ARPI) in taxane-naïve patients with metastatic castration-resistant prostate cancer. At ASCO, data presented showed 177Lu-PSMA-617 delayed time to ...

1. KEYNOTE-361 trial, Abstract 4518 - Quantitative circulating tumor DNA (ctDNA) assessment in patients (pts) with advanced urothelial carcinoma (UC) treated with pembrolizumab (pembro) or platinum-based chemotherapy (chemo) from the phase 3 KEYNOTE-361 trial.
   -- This is particularly important as it...